NBY Relative Valuation
NBY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NBY is overvalued; if below, it's undervalued.
Historical Valuation
NovaBay Pharmaceuticals Inc (NBY) is now in the Fair zone, suggesting that its current forward PS ratio of 61.64 is considered Fairly compared with the five-year average of -2.08. The fair price of NovaBay Pharmaceuticals Inc (NBY) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：10.64
Fair
-6.83
PE
1Y
3Y
5Y
-285.64
EV/EBITDA
NovaBay Pharmaceuticals Inc. (NBY) has a current EV/EBITDA of -285.64. The 5-year average EV/EBITDA is -5.53. The thresholds are as follows: Strongly Undervalued below -55.67, Undervalued between -55.67 and -30.60, Fairly Valued between 19.54 and -30.60, Overvalued between 19.54 and 44.61, and Strongly Overvalued above 44.61. The current Forward EV/EBITDA of -285.64 falls within the Strongly Undervalued range.
-185.67
EV/EBIT
NovaBay Pharmaceuticals Inc. (NBY) has a current EV/EBIT of -185.67. The 5-year average EV/EBIT is -3.60. The thresholds are as follows: Strongly Undervalued below -36.18, Undervalued between -36.18 and -19.89, Fairly Valued between 12.69 and -19.89, Overvalued between 12.69 and 28.98, and Strongly Overvalued above 28.98. The current Forward EV/EBIT of -185.67 falls within the Strongly Undervalued range.
61.64
PS
NovaBay Pharmaceuticals Inc. (NBY) has a current PS of 61.64. The 5-year average PS is 1.60. The thresholds are as follows: Strongly Undervalued below -9.29, Undervalued between -9.29 and -3.85, Fairly Valued between 7.04 and -3.85, Overvalued between 7.04 and 12.48, and Strongly Overvalued above 12.48. The current Forward PS of 61.64 falls within the Strongly Overvalued range.
-180.41
P/OCF
NovaBay Pharmaceuticals Inc. (NBY) has a current P/OCF of -180.41. The 5-year average P/OCF is -4.35. The thresholds are as follows: Strongly Undervalued below -35.86, Undervalued between -35.86 and -20.10, Fairly Valued between 11.41 and -20.10, Overvalued between 11.41 and 27.17, and Strongly Overvalued above 27.17. The current Forward P/OCF of -180.41 falls within the Strongly Undervalued range.
0.00
P/FCF
NovaBay Pharmaceuticals Inc. (NBY) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.07. The thresholds are as follows: Strongly Undervalued below -0.41, Undervalued between -0.41 and -0.17, Fairly Valued between 0.31 and -0.17, Overvalued between 0.31 and 0.54, and Strongly Overvalued above 0.54. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
NovaBay Pharmaceuticals Inc (NBY) has a current Price-to-Book (P/B) ratio of -13.15. Compared to its 3-year average P/B ratio of -0.56 , the current P/B ratio is approximately 2258.20% higher. Relative to its 5-year average P/B ratio of 0.41, the current P/B ratio is about -3345.46% higher. NovaBay Pharmaceuticals Inc (NBY) has a Forward Free Cash Flow (FCF) yield of approximately 0.40%. Compared to its 3-year average FCF yield of -143.06%, the current FCF yield is approximately -100.28% lower. Relative to its 5-year average FCF yield of -112.69% , the current FCF yield is about -100.35% lower.
-13.15
P/B
Median3y
-0.56
Median5y
0.41
0.40
FCF Yield
Median3y
-143.06
Median5y
-112.69
Competitors Valuation Multiple
The average P/S ratio for NBY's competitors is 50.38, providing a benchmark for relative valuation. NovaBay Pharmaceuticals Inc Corp (NBY) exhibits a P/S ratio of 61.64, which is 22.35% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NBY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NBY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NovaBay Pharmaceuticals Inc (NBY) currently overvalued or undervalued?
NovaBay Pharmaceuticals Inc (NBY) is now in the Fair zone, suggesting that its current forward PS ratio of 61.64 is considered Fairly compared with the five-year average of -2.08. The fair price of NovaBay Pharmaceuticals Inc (NBY) is between to according to relative valuation methord.
What is NovaBay Pharmaceuticals Inc (NBY) fair value?
NBY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of NovaBay Pharmaceuticals Inc (NBY) is between to according to relative valuation methord.
How does NBY's valuation metrics compare to the industry average?
The average P/S ratio for NBY's competitors is 50.38, providing a benchmark for relative valuation. NovaBay Pharmaceuticals Inc Corp (NBY) exhibits a P/S ratio of 61.64, which is 22.35% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for NovaBay Pharmaceuticals Inc (NBY) as of Jan 08 2026?
As of Jan 08 2026, NovaBay Pharmaceuticals Inc (NBY) has a P/B ratio of -13.15. This indicates that the market values NBY at -13.15 times its book value.
What is the current FCF Yield for NovaBay Pharmaceuticals Inc (NBY) as of Jan 08 2026?
As of Jan 08 2026, NovaBay Pharmaceuticals Inc (NBY) has a FCF Yield of 0.40%. This means that for every dollar of NovaBay Pharmaceuticals Inc’s market capitalization, the company generates 0.40 cents in free cash flow.
What is the current Forward P/E ratio for NovaBay Pharmaceuticals Inc (NBY) as of Jan 08 2026?
As of Jan 08 2026, NovaBay Pharmaceuticals Inc (NBY) has a Forward P/E ratio of -6.83. This means the market is willing to pay $-6.83 for every dollar of NovaBay Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for NovaBay Pharmaceuticals Inc (NBY) as of Jan 08 2026?
As of Jan 08 2026, NovaBay Pharmaceuticals Inc (NBY) has a Forward P/S ratio of 61.64. This means the market is valuing NBY at $61.64 for every dollar of expected revenue over the next 12 months.